二代测序发现抗TIF1γ阳性副肿瘤性皮肌炎肿瘤中TRIM33体细胞突变
OBJECTIVE: To deep sequence the TRIM33 gene in tumours from patients with cancer-associated anti-TIF1γ autoantibody-positive dermatomyositis (DM) as TRIM33 somatic mutations in tumours may trigger this auto-immune disease.…
要点
- 抗TIF1γ阳性副肿瘤性皮肌炎患者肿瘤中可检出TRIM33体细胞变异。
- 结果支持TRIM33突变触发抗TIF1γ阳性皮肌炎的假说。
核心结论
- 抗TIF1γ阳性副肿瘤性皮肌炎患者肿瘤中存在的TRIM33体细胞突变可能参与该病的病理生理过程。
临床怎么用
- 对疑诊副肿瘤性皮肌炎的患者,可关注肿瘤中TRIM33体细胞突变作为潜在机制标志。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To deep sequence the TRIM33 gene in tumours from patients with cancer-associated anti-TIF1γ autoantibody-positive dermatomyositis (DM) as TRIM33 somatic mutations in tumours may trigger this auto-immune disease. METHODS: Next generation sequencing of tumour DNA samples from patients with cancer-associated anti-TIF1γ autoantibody-positive DM. Fourteen tumours from 13 anti-TIF1γ autoantibody-positive DM individuals were sequenced along with two control tumours from non-DM individuals. RESULTS: Fourteen probable somatic variants from four tumours were identified in the TRIM33 gene. CONCLUSION: These results are in accordance with the previous report of Pinal-Fernandez et al. and support the hypothesis of a role of TRIM33 gene mutations in the pathophysiology of anti-TIF1γ autoantibody-positive DM.
引用
- Cordel N, Derambure C, Coutant S, et al. TRIM33 gene somatic mutations identified by next generation sequencing in neoplasms of patients with anti-TIF1γ positive cancer-associated dermatomyositis. Rheumatology (Oxford). 2021. PMID: 33764396. doi:10.1093/rheumatology/keab260
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。